Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF)
hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in …

Aims We previously reported that in the EMPA-REG OUTCOME® trial, empagliflozin added
to standard of care reduced the risk of 3-point major adverse cardiovascular events …

Background: In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular
Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with type 2 diabetes …

Abstract Aims In the EMPA‐REG OUTCOME trial, empagliflozin reduced risk of death from
heart failure (HF) or hospitalization for heart failure (HHF) versus placebo in patients with …

Background Empagliflozin reduces the risk of major heart failure outcomes in heart failure
with reduced or preserved ejection fraction. Objectives The goal of this study was to evaluate …

Background: Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients with
heart failure with reduced ejection fraction, but additional information is needed about …

OBJECTIVE In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2
Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 …

Background: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event
Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose …

Background: In EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial
in Type 2 Diabetes Mellitus Patients) empagliflozin significantly reduced the risk of …

BACKGROUND: It is not known whether the benefits of sodium-glucose cotransporter 2
inhibitors in heart failure persist after years of therapy. METHODS: In the EMPEROR …